Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
669 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hepatocellular Carcinoma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hepatocellular Carcinoma - Pipeline Review, H2 2014', provides an overview of the Hepatocellular Carcinoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Hepatocellular Carcinoma Overview 8 Therapeutics Development 9 Hepatocellular Carcinoma - Therapeutics under Development by Companies 11 Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes 20 Hepatocellular Carcinoma - Pipeline Products Glance 22 Hepatocellular Carcinoma - Products under Development by Companies 25 Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes 36 Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 38 Hepatocellular Carcinoma - Therapeutics Assessment 143 Drug Profiles 162 Hepatocellular Carcinoma - Recent Pipeline Updates 451 Hepatocellular Carcinoma - Dormant Projects 635 Hepatocellular Carcinoma - Discontinued Products 641 Hepatocellular Carcinoma - Product Development Milestones 643 Appendix 650
List of Tables Number of Products under Development for Hepatocellular Carcinoma, H2 2014 27 Number of Products under Development for Hepatocellular Carcinoma - Comparative Analysis, H2 2014 28 Number of Products under Development by Companies, H2 2014 30 Number of Products under Development by Companies, H2 2014 (Contd..1) 31 Number of Products under Development by Companies, H2 2014 (Contd..2) 32 Number of Products under Development by Companies, H2 2014 (Contd..3) 33 Number of Products under Development by Companies, H2 2014 (Contd..4) 34 Number of Products under Development by Companies, H2 2014 (Contd..5) 35 Number of Products under Development by Companies, H2 2014 (Contd..6) 36 Number of Products under Development by Companies, H2 2014 (Contd..7) 37 Number of Products under Investigation by Universities/Institutes, H2 2014 39 Comparative Analysis by Late Stage Development, H2 2014 40 Comparative Analysis by Clinical Stage Development, H2 2014 41 Comparative Analysis by Early Stage Development, H2 2014 42 Products under Development by Companies, H2 2014 43 Products under Development by Companies, H2 2014 (Contd..1) 44 Products under Development by Companies, H2 2014 (Contd..2) 45 Products under Development by Companies, H2 2014 (Contd..3) 46 Products under Development by Companies, H2 2014 (Contd..4) 47 Products under Development by Companies, H2 2014 (Contd..5) 48 Products under Development by Companies, H2 2014 (Contd..6) 49 Products under Development by Companies, H2 2014 (Contd..7) 50 Products under Development by Companies, H2 2014 (Contd..8) 51 Products under Development by Companies, H2 2014 (Contd..9) 52 Products under Development by Companies, H2 2014 (Contd..10) 53 Products under Investigation by Universities/Institutes, H2 2014 54 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 55 Hepatocellular Carcinoma - Pipeline by 4SC AG, H2 2014 56 Hepatocellular Carcinoma - Pipeline by AbbVie Inc., H2 2014 57 Hepatocellular Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2014 58 Hepatocellular Carcinoma - Pipeline by ACROVIS biostructures GmbH, H2 2014 59 Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H2 2014 60 Hepatocellular Carcinoma - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 61 Hepatocellular Carcinoma - Pipeline by Amgen Inc., H2 2014 62 Hepatocellular Carcinoma - Pipeline by AndroScience Corporation, H2 2014 63 Hepatocellular Carcinoma - Pipeline by ArQule, Inc., H2 2014 64 Hepatocellular Carcinoma - Pipeline by Arrowhead Research Corporation, H2 2014 65 Hepatocellular Carcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 66 Hepatocellular Carcinoma - Pipeline by AstraZeneca PLC, H2 2014 67 Hepatocellular Carcinoma - Pipeline by Avidin Ltd, H2 2014 68 Hepatocellular Carcinoma - Pipeline by Bayer AG, H2 2014 69 Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Limited, H2 2014 70 Hepatocellular Carcinoma - Pipeline by Blueprint Medicines, H2 2014 71 Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 72 Hepatocellular Carcinoma - Pipeline by Boston Biomedical, Inc., H2 2014 73 Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd., H2 2014 74 Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc., H2 2014 75 Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H2 2014 76 Hepatocellular Carcinoma - Pipeline by Celgene Corporation, H2 2014 77 Hepatocellular Carcinoma - Pipeline by Celsion Corporation, H2 2014 78 Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Limited, H2 2014 79 Hepatocellular Carcinoma - Pipeline by Chroma Therapeutics Ltd., H2 2014 80 Hepatocellular Carcinoma - Pipeline by CrystalGenomics, Inc., H2 2014 81 Hepatocellular Carcinoma - Pipeline by CytRx Corporation, H2 2014 82 Hepatocellular Carcinoma - Pipeline by Delcath Systems, Inc., H2 2014 83 Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2014 84 Hepatocellular Carcinoma - Pipeline by Digna Biotech, S.L., H2 2014 85 Hepatocellular Carcinoma - Pipeline by Eisai Co., Ltd., H2 2014 86 Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 87 Hepatocellular Carcinoma - Pipeline by Endocyte, Inc., H2 2014 88 Hepatocellular Carcinoma - Pipeline by Exelixis, Inc., H2 2014 89 Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 90 Hepatocellular Carcinoma - Pipeline by Gamida Cell Ltd., H2 2014 91 Hepatocellular Carcinoma - Pipeline by Genelux Corporation, H2 2014 92 Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H2 2014 93 Hepatocellular Carcinoma - Pipeline by GenSpera, Inc., H2 2014 94 Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline plc, H2 2014 95 Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corporation, H2 2014 96 Hepatocellular Carcinoma - Pipeline by Immune Network, Ltd., H2 2014 97 Hepatocellular Carcinoma - Pipeline by Immunicum AB, H2 2014 98 Hepatocellular Carcinoma - Pipeline by Immunomedics, Inc., H2 2014 99 Hepatocellular Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2014 100 Hepatocellular Carcinoma - Pipeline by Immuron Limited, H2 2014 101 Hepatocellular Carcinoma - Pipeline by In Cell Art, H2 2014 102 Hepatocellular Carcinoma - Pipeline by Incuron, LLC, H2 2014 103 Hepatocellular Carcinoma - Pipeline by Intezyne, Inc, H2 2014 104 Hepatocellular Carcinoma - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 105 Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd., H2 2014 106 Hepatocellular Carcinoma - Pipeline by Kowa Company, Ltd., H2 2014 107 Hepatocellular Carcinoma - Pipeline by La Jolla Pharmaceutical Company, H2 2014 108 Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 109 Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 110 Hepatocellular Carcinoma - Pipeline by MaxCyte, Inc., H2 2014 111 Hepatocellular Carcinoma - Pipeline by Merck KGaA, H2 2014 112 Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 113 Hepatocellular Carcinoma - Pipeline by MolMed S.p.A., H2 2014 114 Hepatocellular Carcinoma - Pipeline by MultiCell Technologies, Inc., H2 2014 115 Hepatocellular Carcinoma - Pipeline by NeoStem, Inc., H2 2014 116 Hepatocellular Carcinoma - Pipeline by Nerviano Medical Sciences, H2 2014 117 Hepatocellular Carcinoma - Pipeline by Novartis AG, H2 2014 118 Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 119 Hepatocellular Carcinoma - Pipeline by Omeros Corporation, H2 2014 120 Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc., H2 2014 121 Hepatocellular Carcinoma - Pipeline by OncoTherapy Science, Inc., H2 2014 122 Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 123 Hepatocellular Carcinoma - Pipeline by Onxeo SA, H2 2014 124 Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 125 Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals, Inc., H2 2014 126 Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 127 Hepatocellular Carcinoma - Pipeline by Pfizer Inc., H2 2014 128 Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corporation, H2 2014 129 Hepatocellular Carcinoma - Pipeline by PhaseRx, Inc., H2 2014 130 Hepatocellular Carcinoma - Pipeline by Polaris Group, H2 2014 131 Hepatocellular Carcinoma - Pipeline by Priaxon AG, H2 2014 132 Hepatocellular Carcinoma - Pipeline by Progen Pharmaceuticals Limited, H2 2014 133 Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H2 2014 134 Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 135 Hepatocellular Carcinoma - Pipeline by Quantum Pharmaceuticals, H2 2014 136 Hepatocellular Carcinoma - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 137 Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc., H2 2014 138 Hepatocellular Carcinoma - Pipeline by Rigontec GmbH, H2 2014 139 Hepatocellular Carcinoma - Pipeline by Santaris Pharma A/S, H2 2014 140 Hepatocellular Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2014 141 Hepatocellular Carcinoma - Pipeline by Shanghai Sunway Biotech Co., Ltd, H2 2014 142 Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd., H2 2014 143 Hepatocellular Carcinoma - Pipeline by Silence Therapeutics plc, H2 2014 144 Hepatocellular Carcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 145 Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H2 2014 146 Hepatocellular Carcinoma - Pipeline by Solasia Pharma K.K., H2 2014 147 Hepatocellular Carcinoma - Pipeline by Synta Pharmaceuticals Corp., H2 2014 148 Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2014 149 Hepatocellular Carcinoma - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 150 Hepatocellular Carcinoma - Pipeline by Therametrics holding AG, H2 2014 151 Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc., H2 2014 152 Hepatocellular Carcinoma - Pipeline by THERAVECTYS SA, H2 2014 153 Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 154 Hepatocellular Carcinoma - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2014 155 Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 156 Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H2 2014 157 Hepatocellular Carcinoma - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 158 Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics, LLC, H2 2014 159 Hepatocellular Carcinoma - Pipeline by Virttu Biologics Limited, H2 2014 160 Assessment by Monotherapy Products, H2 2014 161 Assessment by Combination Products, H2 2014 162 Number of Products by Stage and Target, H2 2014 164 Number of Products by Stage and Mechanism of Action, H2 2014 171 Number of Products by Stage and Route of Administration, H2 2014 177 Number of Products by Stage and Molecule Type, H2 2014 179 Hepatocellular Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 469 Hepatocellular Carcinoma - Dormant Projects, H2 2014 653 Hepatocellular Carcinoma - Dormant Projects (Contd..1), H2 2014 654 Hepatocellular Carcinoma - Dormant Projects (Contd..2), H2 2014 655 Hepatocellular Carcinoma - Dormant Projects (Contd..3), H2 2014 656 Hepatocellular Carcinoma - Dormant Projects (Contd..4), H2 2014 657 Hepatocellular Carcinoma - Dormant Projects (Contd..5), H2 2014 658 Hepatocellular Carcinoma - Discontinued Products, H2 2014 659 Hepatocellular Carcinoma - Discontinued Products (Contd..1), H2 2014 660
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.